Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research23

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research23

FiltersClear all

Status

Recruiting5
Active, not recruiting13
Completed5

Study type

Interventional23

Phase

Phase 38
Phase 1/25
Phase 25
Phase 13
Not applicable2

Investigator

Ashish Saxena3
Eleni Andreopoulou3
Massimo Cristofanilli3
Despina Siolas2
Elizabeta Cristina Popa2

Department

Medicine19
Population Health Sciences2
Neurology1
Radiation Oncology1

Condition

Neoplasm Metastasis23
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug19
Procedure4
Biological3
Radiation2
Behavioral1
Genetic

Sponsor type

Industry16
Other academic3
NIH3
WCM (investigator-initiated)1

Start date

Has results posted7

Interventional×Neoplasm Metastasis×Clear all

Showing 1–20 of 23 studiesSort:

RecruitingInterventional · Phase 1/2NCT03556228 ↗
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

FiltersClear all

Status

Recruiting5
Active, not recruiting13
Completed5

Study type

Interventional23

Phase

Phase 38
Phase 1/25
Phase 25
Phase 13
Not applicable2

Investigator

Ashish Saxena3
Eleni Andreopoulou3
Massimo Cristofanilli3
Despina Siolas2
Elizabeta Cristina Popa2

Department

Medicine19
Population Health Sciences2
Neurology1
Radiation Oncology1

Condition

Neoplasm Metastasis23
Leukemia, Myeloid, Acute50
Prostatic Neoplasms49
Breast Neoplasms41
Heart Failure31

Intervention type

Drug19
Procedure4
Biological3
Radiation2
Behavioral1
Genetic

Sponsor type

Industry16
Other academic3
NIH3
WCM (investigator-initiated)1

Start date

Has results posted7

Interventional×Neoplasm Metastasis×Clear all

Showing 1–20 of 23 studiesSort:

RecruitingInterventional · Phase 1/2NCT03556228 ↗
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma

Show all 14

Show fewer

Manish A Shah2
Anna C Pavlick1
Alana Nguyen1
Cora Sternberg1
Hani Lamie Ashamalla1
Megan Johnson Shen1
Rajiv S. Magge1
Rohit Kumar Jain1
Shoshana Rosenberg1

Show all 50

Show fewer

Neoplasms31
Carcinoma, Non-Small-Cell Lung27
Multiple Myeloma27
Colitis, Ulcerative26
Crohn Disease26
Myelodysplastic Syndromes26
Recurrence25
Atrial Fibrillation23
Obesity23
Parkinson Disease21
COVID-1920
Colorectal Neoplasms18
Depression18
Cardiovascular Diseases17
Hematologic Neoplasms17
HIV Infections16
Non-alcoholic Fatty Liver Disease15
Overweight15
Melanoma13
Idiopathic Pulmonary Fibrosis12
Inflammatory Bowel Diseases12
Leukemia, Lymphocytic, Chronic, B-Cell12
Lung Neoplasms12
Lymphoma, Non-Hodgkin12
Primary Myelofibrosis12
Hypertension11
Myeloproliferative Disorders11
Alzheimer Disease10
Coronary Artery Disease10
Hypertension, Pulmonary10
Leukemia, Myelomonocytic, Chronic10
Stroke10
Urinary Bladder Neoplasms10
Cognitive Dysfunction9
Leukemia9
Lung Diseases, Interstitial9
Pulmonary Arterial Hypertension9
Burkitt Lymphoma8
Carcinoma, Renal Cell8
Chronic Pain8
Fibrosis8
Lymphoma, Follicular8
Lymphoma, Large B-Cell, Diffuse8
Adenocarcinoma Of Esophagus7
Anemia7

Other1

Ashish SaxenaPI

Intervention: Drug: VMD-928 100 mg Tablet · Drug: VMD-928 Tablet and Pembrolizumab (200 mg)
Dates: Jun 2018 – Dec 2027 (est.)
Sponsor: VM Oncology, llc

Head and Neck CarcinomaAdenoid Cystic CarcinomaLung Cancer+22 more

Active, not recruitingInterventional · Phase 2NCT03964727 ↗

A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Ashish SaxenaPI

Intervention: Drug: Sacituzumab Govitecan-hziy
Dates: Oct 2019 – Jan 2025· Results posted
Sponsor: Gilead Sciences, Inc.

Metastatic Solid Tumor

Active, not recruitingInterventional · Phase 2NCT03994796 ↗

Genomically-Guided Treatment Trial in Brain Metastases

Rajiv S. MaggePI

Intervention: Drug: Abemaciclib · Drug: PI3K Inhibitor paxalisib · Drug: Entrectinib · Drug: Adagrasib
Dates: Oct 2019 – Nov 2025· Results posted
Sponsor: Alliance for Clinical Trials in Oncology

CDK Gene MutationMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Solid Neoplasm+4 more

Active, not recruitingInterventional · Phase 1/2NCT04068194 ↗

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Elizabeta Cristina PopaPI

Intervention: Drug: Avelumab · Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Hypofractionated Radiation Therapy · Drug: Peposertib
Dates: Apr 2020 – Jul 2027 (est.)
Sponsor: National Cancer Institute

Locally Advanced Malignant Solid NeoplasmLocally Advanced Unresectable CholangiocarcinomaLocally Advanced Unresectable Gallbladder Carcinoma+7 more

Active, not recruitingInterventional · Phase 1NCT04294628 ↗

Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors

Cora SternbergPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Magnetic Resonance Imaging · Procedure: Multigated Acquisition Scan · Biological: Trastuzumab Deruxtecan
Dates: Sep 2020 – Sep 2025
Sponsor: National Cancer Institute

Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more

RecruitingInterventional · Not applicableNCT04515810 ↗

Planning Advance Care Together (PACT) to Improve Engagement in Advance Care Planning

Megan Johnson ShenPI

Intervention: Other: Internet-Based Intervention · Other: Best Practice · Other: Telephone-Based Intervention · Other: Questionnaire Administration · Other: Post-intervention qualitative feedback interview
Dates: Feb 2025 – May 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Locally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmRecurrent Hematologic Malignancy+1 more

Active, not recruitingInterventional · Phase 1NCT04704661 ↗

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Despina SiolasPI

Intervention: Procedure: Biopsy Procedure · Procedure: Biospecimen Collection · Drug: Ceralasertib · Procedure: Computed Tomography · Procedure: Echocardiography Test · Procedure: Multigated Acquisition Scan · Procedure: Positron Emission Tomography · Biological: Trastuzumab Deruxtecan
Dates: Aug 2021 – Mar 2027 (est.)
Sponsor: National Cancer Institute

Advanced Breast CarcinomaAdvanced Colon CarcinomaAdvanced Colorectal Carcinoma+37 more

Active, not recruitingInterventional · Phase 3NCT04784715 ↗

Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

Eleni AndreopoulouPI

Intervention: Drug: Trastuzumab deruxtecan · Drug: Placebo · Drug: Taxane · Drug: Pertuzumab · Drug: Trastuzumab
Dates: Apr 2021 – May 2027 (est.)
Sponsor: AstraZeneca, PLC

Breast CancerHER2-positiveMetastatic

Active, not recruitingInterventional · Phase 3NCT04964934 ↗

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

Massimo CristofanilliPI

Intervention: Drug: AZD9833 · Drug: AZD9833 Placebo · Drug: Anastrozole · Drug: Anastrozole placebo · Drug: Letrozole · Drug: Letrozole placebo · Drug: Palbociclib · Drug: Abemaciclib · Drug: Luteinizing hormone-releasing hormone (LHRH) agonist · Drug: Ribociclib
Dates: Jun 2021 – Jun 2025
Sponsor: AstraZeneca, PLC

ER-Positive HER2-Negative Breast Cancer

Active, not recruitingInterventional · Phase 3NCT05374512 ↗

A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02)

Eleni AndreopoulouPI

Intervention: Drug: Dato-DXd · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Carboplatin · Drug: Capecitabine · Drug: Eribulin mesylate
Dates: May 2022 – Aug 2025
Sponsor: AstraZeneca, PLC

Breast Cancer

Active, not recruitingInterventional · Phase 3NCT05501886 ↗

Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

Massimo CristofanilliPI

Intervention: Drug: Gedatolisib · Drug: Palbociclib · Drug: Fulvestrant · Drug: Alpelisib
Dates: Dec 2022 – Jun 2026 (est.)
Sponsor: Celcuity, Inc.

Breast Cancer

Active, not recruitingInterventional · Phase 1/2NCT05585320 ↗

A Phase 1/2a, Open-Label, Multicenter, Nonrandomized, Safety and Anti-tumor Activity Study of IMM-1-104, a Novel Oral Dual MEK1/2 Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Anna C PavlickPI

Intervention: Drug: IMM-1-104 Monotherapy (Treatment Group A) · Drug: IMM-1-104 + modified Gemcitabine/nab-Paclitaxel (Treatment Group B) · Drug: IMM-1-104 + modified FOLFIRINOX (Treatment Group C) · Drug: IMM-1-104 + dabrafenib (Treatment Group D) · Drug: IMM-1-104 + pembrolizumab (Treatment Group E)
Dates: Oct 2022 – Jun 2027 (est.)
Sponsor: Immuneering Corporation

Advanced Solid TumorPancreatic AdenocarcinomaMalignant Melanoma (Cutaneous)+1 more

RecruitingInterventional · Phase 1NCT05614739 ↗

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

Rohit Kumar JainPI

Intervention: Drug: Vepugratinib · Drug: Pembrolizumab · Drug: enfortumab vedotin · Drug: Trastuzumab Deruxtecan · Drug: Midazolam · Drug: Digoxin · Drug: Rosuvastatin
Dates: Jan 2023 – Jun 2027 (est.)
Sponsor: Eli Lilly and Company

Urinary Bladder NeoplasmsNeoplasm MetastasisUreteral Neoplasms

Active, not recruitingInterventional · Phase 1/2NCT05669482 ↗

A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination With Avutometinib (VS-6766) and Defactinib in Patients With Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Despina SiolasPI

Intervention: Drug: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel
Dates: Mar 2023 – Aug 2026 (est.)
Sponsor: Verastem

KRAS Activating MutationMetastatic CancerPancreas Cancer+2 more

RecruitingInterventional · Phase 3NCT06103864 ↗

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Massimo CristofanilliPI

Intervention: Drug: Dato-DXd · Drug: Durvalumab · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Gemcitabine · Drug: Carboplatin · Drug: Pembrolizumab
Dates: Nov 2023 – Jul 2027 (est.)
Sponsor: AstraZeneca, PLC

Breast Cancer

Active, not recruitingInterventional · Phase 2NCT06246110 ↗

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer

Ashish SaxenaPI

Intervention: Drug: EIK1001 · Drug: Pembrolizumab · Drug: Paclitaxel · Drug: Pemetrexed · Drug: Carboplatin
Dates: Feb 2024 – Dec 2026 (est.)
Sponsor: Eikon Therapeutics INC

NSCLC

Active, not recruitingInterventional · Phase 3NCT06500455 ↗

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases

Hani Lamie AshamallaPI

Intervention: Procedure: Computed Tomography · Radiation: Fractionated Stereotactic Radiation Therapy · Procedure: Magnetic Resonance Imaging · Radiation: Stereotactic Radiosurgery
Dates: Dec 2024 – Jun 2028 (est.)
Sponsor: NRG Oncology

Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Digestive System Carcinoma+7 more

RecruitingInterventional · Not applicableNCT07635147 ↗

Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)

Shoshana RosenbergPI

Intervention: Behavioral: Decision Support Tool
Dates: Jun 2026 – Sep 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Breast Cancer MetastaticAdvanced Breast CancerStage 4 Breast Cancer+1 more

CompletedInterventional · Phase 3NCT03734029 ↗

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Eleni AndreopoulouPI

Intervention: Drug: Trastuzumab deruxtecan (DS-8201a) · Drug: Capecitabine · Drug: Eribulin · Drug: Gemcitabine · Drug: Paclitaxel · Drug: Nab-paclitaxel
Dates: Dec 2018 – Jan 2022· Results posted
Sponsor: Daiichi Sankyo, Inc.

Breast Cancer

CompletedInterventional · Phase 3NCT03764293 ↗

A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib Mesylate Versus Sorafenib as First-Line Therapy in Patients With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy

Elizabeta Cristina PopaPI

Intervention: Drug: SHR-1210 · Drug: Apatinib · Drug: Sorafenib
Dates: Jun 2019 – Feb 2022· Results posted
Sponsor: Jiangsu Hengrui Medicine Co., Ltd.

Locally Advanced or Metastatic and Unresectable HCC

‹ Prev1 2 Next ›